FDA Issues CRL for Vatiquinone in Friedreich Ataxia, Requests More Efficacy Data
Written by
American Journal Managed Care
Published
0
comments
0
min
Today, the FDA issued a complete response letter (CRL) for vatiquinone (PTC Therapeutics), delaying its potential approval as a treatment for Friedreich ataxia amid efficacy concerns.